DelMar Pharmaceuticals (NSDQ:DMPI) said today that the FDA granted its lead product candidate, VAL-083, fast track status for approval as a therapy for recurrent glioblastoma.
The designation applies to a Phase II trial with the University of Texas MD Anderson Cancer Center and a Phase III trial in patients whose disease has progressed after treatment with temozolomide and bevacizumab.
Get the full story at our sister site, Drug Delivery Business News.